Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 493, Issue 1-2, Pages 75-85Publisher
ELSEVIER
DOI: 10.1016/j.ijpharm.2015.07.055
Keywords
Nanostructured lipid carriers; Sorafenib; Drug release; Angiogenesis inhibitor; Hepatocarcinoma
Categories
Funding
- Italian Ministero dell'Istruzione, dell'Universita e della Ricerca (Ministry for Education, Universities and Research) - MIUR FIRB-MERIT [RBNE08YYBM]
- Biotecnologie Cellulari e Molecolari e Biosensori per il Monitoraggio della Salute dell'Uomo [22]
Ask authors/readers for more resources
Here, the potential of two nanostructured lipid carriers (NLC) for controlled release of sorafenib was evaluated. The obtained systems showed characteristics suitable as drug delivery systems for the treatment of hepatocellular carcinoma (HCC) through parenteral administration. The use of a mixture between a solid lipid (tripalmitin) with a liquid lipid (Captex 355 EP/NF or Miglyol 812) to prepare NLC systems could give a higher drug loading capacity and a longer term stability during storage than that obtained by using only solid lipids. The obtained nanoparticles showed a nanometer size and high negative zeta potential values. Scansion electron microscopy (SEM) of the sorafenib loaded NLC revealed a spherical shape with a diameter < 300 nm. In vitro biological studies demonstrated that sorafenib loaded into NLC had enhanced anti-tumor activity compared to that of free drug. This finding raises hope in terms of future drug delivery strategy of sorafenib loaded NLC, that can be useful for therapeutic application in HCC. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available